Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Veru Inc
VERUCurrent price
0.52 USD
+0.0094 USD (+1.85%)
Last closed
0.52 USD
Company
www.verupharma.com
ISIN
US92536C1036
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
114 969 992 USD
Yield for 12 month
-15.20 %
1Y
3Y
5Y
10Y
15Y
VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Address: 2916 North Miami Avenue, Miami, FL, United States, 33127
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
3.40 USDP/E ratio
–Dividend Yield
–Current Year
+16 886 419 USD
Last Year
+16 296 958 USD
Current Quarter
+3 953 870 USD
Last Quarter
+4 135 301 USD
Current Year
+5 853 977 USD
Last Year
+7 565 928 USD
Current Quarter
+1 338 015 USD
Last Quarter
+678 299 USD
Key Figures VERU
1 year
3 years
5 years
10 years
EBITDA
-65 041 396 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-64.36 %
PEG Ratio
–
Return On Equity TTM
-126.72 %
Wall Street Target Price
3.40 USD
Revenue TTM
14 091 909 USD
Book Value
0.26 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
18.30 %
Dividend Yield
–
Gross Profit TTM
30 591 388 USD
Earnings per share
-0.30 USD
Diluted Eps TTM
-0.30 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-265.42 %
Dividend Analytics VERU
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
3 years5Y Average Payout Ratio
–Dividend History VERU
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
28.04.2014
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
3
Consistent Years
4
Continuous Dividends
5
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation VERU
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
117.65
Enterprise Value Revenue
7.06
Price Sales TTM
8.16
Enterprise Value EBITDA
-3.23
Price Book MRQ
3.06
Financials VERU
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators VERU
For 52 weeks
0.36 USD
1.92 USD
50 Day MA
0.76 USD
Shares Short Prior Month
12 804 952
200 Day MA
0.90 USD
Short Ratio
13.35
Shares Short
12 695 574
Short Percent
9.70 %
BeatStart